Aravive Inc. (ARAV) Prices 3.33M Share Common Offering at $7.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St edges lower as chips fall; markets assess big bank earnings
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- CoreWeave stock drops on insider selling notice
- Sysco calls on Teamsters to end LA strike after economic deal reached
Aravive Announces Pricing of Public Offering of Common Stock
November 27, 2019 8:30 AM ESTHOUSTON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (Aravive) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced the pricing of its previously announced underwritten public offering of 3,333,334 shares of its common stock at a public offering price of $7.50 per share. Â Aravive expects to receive gross proceeds of approximately $25 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Aravive.
In connection with this offering, Aravive has granted the... More



